Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum C21 Investments Inc C.CXXI

Alternate Symbol(s):  CXXIF

C21 Investments Inc. is a Canada-based vertically integrated cannabis company that cultivates, processes and distributes cannabis and hemp-derived consumer products in the United States. The Company is focused on value creation through the disciplined acquisition and integration of core retail, manufacturing, and distribution assets in strategic markets with multi-market branded consumer... see more

Bullboard (CSE:CXXI)

View:
Post by mercedesmanon Jan 07, 2022 5:22pm

New to this play...

I like what I see in terms of insider buying and positve earnings per share (a rareity in this sector) Has anyone heard what the motivation is behind the move to US GAAP as announced in November ...more  
Comment by MuttleyKnowson Dec 17, 2021 10:47pm

RE:low volume

I already told you why revenue is not increasing in Q3. There is weakness across the industry post lockdown. People aren't stuck at home anymore. Look for a revenue bump in Q4 numbers. Organic ...more  
Post by charliebitmyfinon Dec 17, 2021 10:09am

low volume

revenue not increasing, not so encouraging
Post by AwareInvestoron Dec 16, 2021 8:58am

C21 Sees Revenue Of US$8.2 Million For Q3 2021, Net Income

C21 Investments this morning posted its third quarter 2021 financial results, recording revenue of US$8.2 million for the three month period. Net income meanwhile came in at US$3.3 million. https: ...more  
Comment by hevinon Dec 10, 2021 12:08pm

RE:RE:RE:Should be less than 3 weeks til results.

The Cannabis sector has been weak over the last 6 months because of heavy (possibly illegal) shorting and even in the last week c21 had anywhere between 14 and 58% approximately shorting... Very ...more  
Comment by hevinon Dec 09, 2021 11:47am

RE:RE:Should be less than 3 weeks til results.

I hope you're wrong about a softer quarter. My guess is that it might be a little higher in that customers can go out to the pot stores now, not to mention that more people are making the switch ...more  
Comment by MuttleyKnowson Dec 09, 2021 9:55am

RE:Should be less than 3 weeks til results.

Results should be out soon. Most likely next week. I would expect that everyone would like to have Christmas week off.  Expect softer Q over Q numbers as there is weakness across the sector ...more  
Post by hevinon Dec 08, 2021 9:17pm

Should be less than 3 weeks til results.

Because the last was September 28th. Of course I could be wrong. LOL muttley?
Post by Jnids1on Dec 06, 2021 10:14am

Market Closed

Does anyone know why the market is not open today?
Comment by MuttleyKnowson Dec 06, 2021 9:53am

RE:down to mid 40's again?

Anything is possible in these crazy markets. There is value here even if you just want to trade the swings. 
Post by charliebitmyfinon Dec 05, 2021 8:13am

down to mid 40's again?

and then another run up over 2 bucks can it happen again maybe 
Post by hevinon Nov 22, 2021 4:28pm

Increased flower yield, GAAP, and eliminating phantom shares

https://stockhouse.com/news/press-releases/2021/11/18/c21-investments-announces-transition-to-u-s-gaap-for-q4
Post by Richardson35on Nov 17, 2021 10:17pm

🎉📣FSD Pharma's Research and Clinical Advisory Board📢

Dr. Eleanor N. Fish, a world-renowned immunologist and cytokine expert, has been appointed to FSD Pharma's Research and Clinical Advisory Board. FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities